Serum-free Media Market Size To Reach $3.84 Billion By 2030

Serum-free Media Market Growth & Trends

The global serum-free media market size is expected to reach USD 3.84 billion by 2030, registering a CAGR of 13.03% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of infectious and chronic diseases, coupled with the growing focus on cell-based therapeutics, is increasing the market's growth prospects. In addition, growing funding for the cell-based research is the key factor driving the serum-free media market.

The use of serum-free media has increased considerably during the past 15 years. This is mainly true in industrial applications, wherein the use of serum during the manufacturing of biopharmaceuticals poses a risk to safety and a source of unwanted contamination. Moreover, Serum-free cell culture media improves the experimental constancy by reducing the number of unknown culture components and the effects of unknown growth factors, hormones, and vitamins.

In addition, serum-free media has numerous advantages, such as reducing the cost and inconvenience of batch testing sera, eliminating the uncertainty about global supply fluctuations, and simplifying downstream processing and purification, another major factor driving the market growth.

Although CAR T-cell therapies have made breakthroughs in treating hematological malignancies, their accessibility to patients is constrained by the complexity and expense of their manufacturing. Beyond the effectiveness of your CAR-T product, one difficulty in CAR T-cell production is achieving constant growth of T cells made available following gene transfer. Therefore, optimizing the media to stimulate T-cell proliferation is one of the most important factors.

Yet, creating media that permits constant growth while meeting regulatory quality criteria has proven challenging. However, new developments in cell culture techniques have enhanced output and functionality in CAR T-cell workflows utilizing serum-free media, enabling the construction of large-scale regulatory-compliant processes capable of producing billions of T cells quickly.

For instance, the Vero cell line, which was derived from the kidney of an African green monkey, has been widely applied to the production of viral vaccines. Moreover, it has been utilized to manufacture several SARS-CoV variants. For instance, Lonza Bioscience's ProVeroTM1 Serum-free Medium is a protein-free non-animal origin medium intended to support the development of Vero cells and MDCK. In addition, HEKin1, manufactured by HiMedia Labs, was used to manufacture COVISHIELD, a COVID-19 vaccine containing recombinant SARS-CoV-2 spike (S) glycoprotein. This vaccine has been manufactured using genetically modified HEK293 cells.

On the other hand, the slow growth rate of SFM as compared to the serum media, and the requirement of different cell types to prepare specific media formulations and cell clumping when passaging can be the restraining factors.

 Request a free sample copy or view report summary: Serum-free Media Market Report

Serum-free Media Market Report Highlights

• By product, the CHO Media segment held the largest share of the serum-free media market. CHO media is a critical component of CHO cell line maintenance procedures involved in development and commercialization of several bio therapeutics. Commercially available CHO media are chemically defined and animal component-free, which increases their applications in the biopharmaceutical industry

• By application, the biopharmaceutical production segment held a larger share of the global serum-free media market. Rise in burden of chronic diseases, such as cancer, autoimmune diseases, etc., has driven demand for the targeted treatment options, such as monoclonal antibodies (mAbs) have led to increase in adoption of serum free cell culture media in bioprocessing operations

• By end-user, the biopharmaceutical & pharmaceutical companies segment held a larger share in 2022, owing to the increasing availability and variety of media types in various serum-free forms has led to increase in adoption of cell culture media in bioprocessing operations

• North America dominated the global serum-free media market in 2022. This can be attributed to the presence of well-established healthcare infrastructure and key market players in the region. Furthermore, increase in R&D activities and growing biopharmaceutical investments in the region are driving the adoption of serum free cell culture media

• Asia Pacific is expected to grow considerably in the future owing to the rising demand for the novel therapeutics, increasing R&D investment by the governments, and rapid infrastructural development are the factors that are boosting the regional growth

Serum-free Media Market Segmentation

Grand View Research has segmented the global serum-free media market based on the product, application, type, end-user, and region:

Serum-free Media Product Outlook (Revenue, USD Million, 2018 - 2030)

• CHO Media

• HEK 293 Media

• BHK Medium

• Vero Medium

• Stem Cell Medium

• Other Serum-free Media

Serum-free Media Application Outlook (Revenue, USD Million, 2018 - 2030)

• Biopharmaceutical Production          

  • Monoclonal Antibodies

  • Vaccines Production

  • Other Therapeutic Proteins

• Tissue Engineering & Regenerative Medicine

Serum-free Media Type Outlook (Revenue, USD Million, 2018 - 2030)

• Liquid Media

• Semi-solid & Solid Media

Serum-free Media End-user Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical & Biotechnology Companies

• Research & Academic Institutes

• Other End-users

Serum-free Media Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Serum-free Media Market

• Thermo Fisher Scientific Inc.

•  Sartorius AG

• Merck KgaA

• Lonza Group AG

• Danaher

• FUJIFILM Holdings Corporation

• MP Bio medicals

• Corning Incorporated

• PAN-Biotech

• R&D Systems, Inc.